



Mérieux Equity Partners Announces Agreement to Sell Majority of its Stake in Swixx Biopharma

Lyon/Paris – December 15th. Mérieux Equity Partners is pleased to announce that an agreement has been signed with SK Capital to sell the majority of its stake in Swixx Biopharma, a portfolio company of Mérieux Participations 4 (“MP4”).

Swixx Biopharma is a leading commercialization partner for Pharma and Biotech. It operates as a one stop shop, single point of contact on downstream segments in the pharma value chain. Its services cover regulatory, distribution, logistics, customer service, market access and launch execution, patient support, sales, marketing, and pharmacovigilance.

Since Mérieux Equity Partners invested in 2021, the company has expanded from a player focused on Central and Eastern Europe to a Multi-Regional Leader, also active in Latin America and the MENA region. The company has experienced exceptional growth, from revenues of approximately €220 million in 2021 to an expected €1.3 billion in 2026. This growth has been achieved mainly organically, through new contracts with major pharma such as Sanofi and Lundbeck, and has been accelerated by the acquisition of Biopas in 2024. The transaction with SK Capital values the Company in excess of €1.5 billion.

Benefiting from an attractive pipeline of customers, Swixx Biopharma is poised to accelerate its development and become a worldwide leader in its field in the coming years.

The company being controlled by the founders and the management, Mérieux Equity Partners has been a significant minority investor since 2021. The fund will exit a large majority of its stake and will remain a shareholder to continue supporting the company in the coming years.

Jean-François Billet, Managing Partner and Head of Buyout at Mérieux Equity Partners, states: “Swixx Biopharma is a perfect example of the value of Mérieux Equity Partners’ expertise in healthcare and of our agile investment strategy. We were able to spot early on the potential of Swixx Biopharma business model in the pharma service market and to support this entrepreneurial journey alongside highly experienced founders and managers. We are proud of this early liquidity event for our investors, and excited to continue supporting the company in its next phase of growth.”

Jean-Michel Lespinasse, CEO of Swixx Biopharma, commented: “This partnership marks a pivotal moment for Swixx, bringing both additional capital and expertise to drive our growth. We remain committed to expanding our role as the trusted partner for leading global biopharmaceutical companies, delivering sustainable outsourcing solutions in complex and emerging markets—and ultimately improving access and outcomes for patients.”

Aaron Davenport, Managing Director of SK Capital, commented: “We are excited to partner with Swixx Biopharma, a company that shares our commitment to improving patient outcomes and advancing healthcare. Our investment underscores confidence in Swixx’s leadership and its ability to deliver sustainable business growth across diverse markets.”



About Mérieux Equity Partners - www.merieux-partners.com

Founded in 2009, Mérieux Equity Partners ("MxEP") is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.6bn of AuM.

Mérieux Participations 4 is a 2021 vintage fund, still in its investment period. Until now, the fund has completed 11 healthcare investments in Europe.

About Swixx Biopharma

Swixx Biopharma is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Biopharma operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With a presence in 45 countries and sales expected to exceed €1.3 billion in 2026, Swixx is one of the fastest-growing independent biopharma commercialization platforms. Gathering outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof, Swixx Biopharma expects to finish 2025 with more than 1,600 employees on board. For more information about Swixx, please visit: www.swixxbiopharma.com.

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

About SK Capital

SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately \$10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.

[Press contacts](#)

MHP Group: James McFarlane (james.mcfarlane@mhpgroup.com), Matthew Taylor (matthew.taylor@mhpgroup.com)